Bristol Myers Squibb deploys Nvidia AI supercomputer

Bristol Myers Squibb is significantly expanding its artificial intelligence capabilities with a major new investment in computing infrastructure from Nvidia, a move the pharmaceutical giant says will accelerate and improve its drug discovery pipeline. The company announced on July 20 that it is deploying a second Nvidia DGX SuperPOD, this one built on the new Vera Rubin architecture, making it the most powerful and energy-efficient AI computing cluster in the life sciences industry.

The new system, comprising eight DGX Vera Rubin NVL72 racks, delivers up to ten times the performance per megawatt compared to the company's previous infrastructure. This expansion builds on a partnership with Nvidia that began approximately three years ago when Bristol Myers Squibb installed its first SuperPOD. Company executives stated that the initial system has already produced compelling results, leading to the decision to invest in the latest generation of hardware.

The primary goal is to democratize access to high-performance computing across the global research organization. Instead of restricting the resource to a small group of specialists, the company plans to integrate both SuperPODs into...